Om

Sensorion SA is a French clinical-stage biotechnology company focused on developing therapies for inner ear disorders and hearing loss. The company works on targeted treatment approaches for conditions such as sudden sensorineural hearing loss, cisplatin-induced ototoxicity, cochlear implantation-related hearing preservation, and inherited forms of deafness. Its portfolio includes small-molecule and gene therapy programs designed to address unmet needs in audiology and vestibular health. Sensorion SA also conducts research across molecular biology, toxicology, and clinical development to support its drug candidates. Headquartered in Montpellier, France, Sensorion SA operates as a specialized biotech player in the healthcare sector, with a business model centered on advancing innovative therapies for patients affected by hearing and balance disorders.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SENSORION MED ENDAVU: Køb Sensorion ($ALSEN) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Sensorion, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.